AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.

Avtozma is the 12th biosimilar from Celltrion to receive approval from the EC. Credit: © CELLTRION INC. All Rights Reserved.

The US Food and Drug Administration (FDA) has granted approval for Celltrion's Avtozma (tocilizumab-anoh) in both intravenous and subcutaneous formulations as an Actemra biosimilar for treating ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been ...